Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Puxitatug samrotecan - AstraZeneca

Next Previous
Drug Profile

Puxitatug samrotecan - AstraZeneca

Alternative Names: AZD-8205

Latest Information Update: 02 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 30 Jun 2025 AstraZeneca plans a phase III Bluestar-Endometrial01 trial for Endometrial cancer (Recurrent, Metastatic disease, Second-line therapy or greater, Monotherapy) in Unknown location (IV, Infusion) in July 2025 (NCT07044336)
  • 13 Sep 2024 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 14 Apr 2023 Pharmacodynamics data from preclinical trials in Ovarian cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top